GlassScriptPhysician profile
Stephanie Barnes
NPI 1265890685
$6,740.23
in general payments reported to CMS, 2019-2025
36 companies · $1,632 in 2025
The $1,632 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $649 · 2022: $1,039 · 2023: $1,738 · 2024: $1,682 · 2025: $1,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,890 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,890.15 |
| Education | $161.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,071.74 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $727.03 | 2021-2025 | Jardiance, Spiriva Respimat |
| Astellas Pharma US INC | $559.64 | 2021-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $553.76 | 2021-2025 | |
| Pfizer INC. | $550.65 | 2023-2025 | |
| Novo Nordisk INC | $490.74 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $462.54 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $323.65 | 2022-2025 | Rexulti, Abilify Maintena |
| Novartis Pharmaceuticals Corporation | $307.13 | 2022-2025 | |
| Glaxosmithkline, LLC. | $276.20 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $244.89 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Myriad Genetic Laboratories, INC. | $214.52 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $202.52 | 2024-2025 | Zenpep |
| Abbott Laboratories | $80.48 | 2022-2024 | Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $79.11 | 2024-2025 | Voquezna |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $73.82 | 2021-2024 | Trintellix |
| Amgen INC. | $61.64 | 2022-2024 | Otezla, Repatha |
| Esperion Therapeutics, INC. | $50.47 | 2024-2025 | Nexletol |
| Nestle Healthcare Nutrition INC. | $43.16 | 2021-2022 | |
| Verona Pharma, INC. | $33.25 | 2025 | Ohtuvayre |
| Xeris Pharmaceuticals, INC. | $30.38 | 2024 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $29.50 | 2024 | Eliquis |
| Almatica Pharma LLC | $26.03 | 2022 | |
| Philips North America LLC | $25.63 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $23.96 | 2024 | Gemtesa |
| Vertex Pharmaceuticals Incorporated | $23.70 | 2025 | |
| Dexcom, INC. | $21.75 | 2021 | |
| Antares Pharma, INC. | $21.06 | 2023 | Tlando, Xyosted, Nocdurna |
| Sanofi-Aventis U.S. LLC | $19.76 | 2021 | |
| Collegium Pharmaceutical, INC. | $18.78 | 2025 | Jornay Pm |
| Viatris Specialty LLC | $17.20 | 2025 | Yupelri |
| Harmony Biosciences LLC | $16.80 | 2023 | Wakix |
| Medtronic, INC. | $15.47 | 2024 | Minimed 780g |
| Axsome Therapeutics, INC. | $15.08 | 2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $14.20 | 2022 | |
| Uswm, LLC | $13.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.